Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy | 12 | 2023 | 137 | 1.390 |
Why?
|
| Amyloidosis | 2 | 2025 | 38 | 1.090 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2025 | 4 | 0.940 |
Why?
|
| Multiple Myeloma | 5 | 2014 | 45 | 0.880 |
Why?
|
| Heart Failure | 2 | 2025 | 298 | 0.880 |
Why?
|
| Cardiomyopathies | 1 | 2025 | 63 | 0.870 |
Why?
|
| Neoplasms | 6 | 2024 | 1341 | 0.820 |
Why?
|
| Antigens, Neoplasm | 6 | 2015 | 77 | 0.760 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2023 | 225 | 0.760 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 2 | 0.700 |
Why?
|
| Hand Dermatoses | 1 | 2021 | 2 | 0.700 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 7 | 0.690 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 287 | 0.670 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 40 | 0.670 |
Why?
|
| Hepatitis C, Chronic | 1 | 2021 | 44 | 0.660 |
Why?
|
| Leadership | 1 | 2021 | 84 | 0.650 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2020 | 1 | 0.650 |
Why?
|
| Myocarditis | 1 | 2020 | 24 | 0.630 |
Why?
|
| Education, Medical | 1 | 2021 | 117 | 0.620 |
Why?
|
| Factor VII Deficiency | 1 | 2019 | 1 | 0.610 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2019 | 1 | 0.610 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2019 | 1 | 0.610 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2019 | 2 | 0.610 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 8 | 0.600 |
Why?
|
| Trisomy | 1 | 2019 | 11 | 0.600 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 14 | 0.600 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 36 | 0.580 |
Why?
|
| Glioblastoma | 1 | 2019 | 69 | 0.560 |
Why?
|
| Humans | 43 | 2025 | 42163 | 0.530 |
Why?
|
| Public Health | 1 | 2021 | 405 | 0.510 |
Why?
|
| Testis | 3 | 2012 | 203 | 0.500 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2015 | 933 | 0.460 |
Why?
|
| Hematologic Neoplasms | 2 | 2011 | 18 | 0.420 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 959 | 0.420 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2024 | 13 | 0.410 |
Why?
|
| Papillomaviridae | 1 | 2014 | 136 | 0.400 |
Why?
|
| Membrane Proteins | 6 | 2015 | 548 | 0.390 |
Why?
|
| Male | 19 | 2025 | 22779 | 0.380 |
Why?
|
| Diagnosis, Differential | 2 | 2025 | 236 | 0.380 |
Why?
|
| Lung Neoplasms | 5 | 2023 | 479 | 0.360 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2011 | 27 | 0.360 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 168 | 0.350 |
Why?
|
| Prostatic Neoplasms | 2 | 2019 | 1068 | 0.350 |
Why?
|
| Ovarian Neoplasms | 5 | 2014 | 406 | 0.330 |
Why?
|
| HIV Infections | 2 | 2023 | 2535 | 0.320 |
Why?
|
| Genistein | 1 | 2010 | 43 | 0.320 |
Why?
|
| Antigens, Surface | 4 | 2015 | 50 | 0.320 |
Why?
|
| Anticarcinogenic Agents | 1 | 2010 | 74 | 0.310 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 363 | 0.310 |
Why?
|
| Neoplasm Proteins | 3 | 2008 | 228 | 0.310 |
Why?
|
| Cell Cycle | 1 | 2010 | 348 | 0.290 |
Why?
|
| Carrier Proteins | 4 | 2015 | 318 | 0.280 |
Why?
|
| Female | 19 | 2022 | 24018 | 0.260 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2025 | 1 | 0.240 |
Why?
|
| Hypotension, Orthostatic | 1 | 2025 | 6 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 290 | 0.220 |
Why?
|
| Galectin 3 | 2 | 2014 | 29 | 0.220 |
Why?
|
| Stroke Volume | 1 | 2025 | 122 | 0.220 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2015 | 29 | 0.210 |
Why?
|
| Apoptosis | 2 | 2014 | 1541 | 0.210 |
Why?
|
| A Kinase Anchor Proteins | 2 | 2015 | 11 | 0.210 |
Why?
|
| Dependovirus | 3 | 2014 | 16 | 0.210 |
Why?
|
| Mucins | 1 | 2024 | 69 | 0.200 |
Why?
|
| Histoplasmosis | 1 | 2023 | 3 | 0.200 |
Why?
|
| Adult | 7 | 2023 | 13458 | 0.200 |
Why?
|
| Sarcoma, Kaposi | 1 | 2023 | 24 | 0.200 |
Why?
|
| Herpesvirus 8, Human | 1 | 2023 | 29 | 0.190 |
Why?
|
| Coccidioidomycosis | 1 | 2023 | 53 | 0.190 |
Why?
|
| Iron | 1 | 2024 | 247 | 0.190 |
Why?
|
| Pneumonia | 1 | 2023 | 60 | 0.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 21 | 0.180 |
Why?
|
| Genital Neoplasms, Female | 1 | 2022 | 17 | 0.180 |
Why?
|
| Nephrotic Syndrome | 1 | 2021 | 11 | 0.180 |
Why?
|
| Cytomegalovirus | 2 | 2014 | 49 | 0.180 |
Why?
|
| Fenretinide | 1 | 2021 | 9 | 0.170 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2021 | 100 | 0.170 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 174 | 0.170 |
Why?
|
| Glucocorticoids | 1 | 2021 | 92 | 0.170 |
Why?
|
| HIV | 1 | 2021 | 100 | 0.170 |
Why?
|
| Cell Line, Tumor | 7 | 2015 | 2598 | 0.160 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 94 | 0.150 |
Why?
|
| Kidney | 1 | 2021 | 363 | 0.150 |
Why?
|
| Thoracic Vertebrae | 1 | 2019 | 8 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2019 | 30 | 0.150 |
Why?
|
| Nigeria | 1 | 2019 | 92 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 130 | 0.150 |
Why?
|
| Ultrasonography | 1 | 2019 | 132 | 0.140 |
Why?
|
| Spinal Cord | 1 | 2019 | 109 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 502 | 0.140 |
Why?
|
| Middle Aged | 5 | 2021 | 11819 | 0.140 |
Why?
|
| Breast | 1 | 2019 | 139 | 0.140 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2015 | 31 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 979 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 246 | 0.130 |
Why?
|
| Aged | 4 | 2025 | 7982 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 573 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 577 | 0.120 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2014 | 5 | 0.110 |
Why?
|
| Animals | 10 | 2024 | 16695 | 0.110 |
Why?
|
| Genitalia | 1 | 2014 | 18 | 0.110 |
Why?
|
| Liver Neoplasms | 2 | 2007 | 211 | 0.110 |
Why?
|
| Dendritic Cells | 3 | 2011 | 130 | 0.110 |
Why?
|
| Gene Transfer Techniques | 1 | 2014 | 53 | 0.100 |
Why?
|
| Organ Specificity | 2 | 2011 | 141 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2014 | 86 | 0.100 |
Why?
|
| Fatal Outcome | 2 | 2024 | 46 | 0.100 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 129 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 165 | 0.100 |
Why?
|
| RNA, Messenger | 4 | 2015 | 1265 | 0.100 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2012 | 25 | 0.100 |
Why?
|
| Thrombolytic Therapy | 1 | 2012 | 25 | 0.100 |
Why?
|
| Thrombosis | 1 | 2012 | 81 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2014 | 164 | 0.090 |
Why?
|
| Cancer Vaccines | 2 | 2011 | 26 | 0.090 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2011 | 8 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 534 | 0.090 |
Why?
|
| Immunologic Surveillance | 1 | 2011 | 7 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2012 | 81 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 144 | 0.080 |
Why?
|
| Calmodulin-Binding Proteins | 4 | 2015 | 10 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 273 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 187 | 0.080 |
Why?
|
| Muramidase | 1 | 2010 | 31 | 0.080 |
Why?
|
| Mitochondrial Membranes | 1 | 2010 | 41 | 0.080 |
Why?
|
| Peptides | 1 | 2012 | 357 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 196 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 177 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2008 | 16 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 378 | 0.070 |
Why?
|
| Immediate-Early Proteins | 1 | 2008 | 50 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 207 | 0.070 |
Why?
|
| Young Adult | 1 | 2019 | 4936 | 0.070 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 80 | 0.070 |
Why?
|
| Hepatectomy | 1 | 2007 | 5 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2008 | 154 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2008 | 181 | 0.070 |
Why?
|
| Plasmids | 1 | 2008 | 247 | 0.070 |
Why?
|
| Neoplasms, Experimental | 1 | 2007 | 38 | 0.070 |
Why?
|
| Trans-Activators | 1 | 2008 | 190 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 253 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2008 | 201 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2010 | 875 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 522 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2007 | 158 | 0.060 |
Why?
|
| Mice, Inbred NOD | 3 | 2011 | 50 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2008 | 461 | 0.060 |
Why?
|
| Clinical Trials as Topic | 3 | 2012 | 249 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 7 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2004 | 16 | 0.050 |
Why?
|
| Cardiovascular System | 1 | 2024 | 37 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2011 | 411 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2004 | 95 | 0.050 |
Why?
|
| Histoplasma | 1 | 2023 | 6 | 0.050 |
Why?
|
| Fluconazole | 1 | 2023 | 41 | 0.050 |
Why?
|
| Mice | 5 | 2014 | 6490 | 0.050 |
Why?
|
| Pelvis | 1 | 2022 | 15 | 0.050 |
Why?
|
| Proteinuria | 1 | 2021 | 55 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 2803 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 11 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2023 | 169 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 1679 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 55 | 0.040 |
Why?
|
| California | 1 | 2023 | 531 | 0.040 |
Why?
|
| Prognosis | 1 | 2022 | 850 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 729 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2008 | 158 | 0.030 |
Why?
|
| Disease Progression | 2 | 2012 | 661 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 649 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2011 | 1420 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2015 | 105 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 116 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 53 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 88 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2014 | 92 | 0.030 |
Why?
|
| Transgenes | 1 | 2014 | 65 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2015 | 112 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 1554 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 137 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 284 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 237 | 0.020 |
Why?
|
| Protamines | 1 | 2012 | 20 | 0.020 |
Why?
|
| Aorta | 1 | 2014 | 197 | 0.020 |
Why?
|
| Albumins | 1 | 2012 | 32 | 0.020 |
Why?
|
| Heparin | 1 | 2012 | 39 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2012 | 29 | 0.020 |
Why?
|
| Anions | 1 | 2012 | 44 | 0.020 |
Why?
|
| Static Electricity | 1 | 2012 | 85 | 0.020 |
Why?
|
| Prodrugs | 1 | 2012 | 31 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2012 | 57 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2012 | 58 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2012 | 69 | 0.020 |
Why?
|
| CpG Islands | 1 | 2012 | 107 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2012 | 40 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2012 | 80 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 534 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 254 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2011 | 57 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1266 | 0.020 |
Why?
|
| Temperature | 1 | 2012 | 314 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 692 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 150 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 640 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2011 | 165 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 68 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 233 | 0.020 |
Why?
|
| Lung | 1 | 2012 | 484 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2012 | 393 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 21 | 0.020 |
Why?
|
| Sperm Tail | 1 | 2008 | 4 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 196 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 1010 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 428 | 0.020 |
Why?
|
| Germ Cells | 1 | 2008 | 74 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2007 | 34 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 65 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 58 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2007 | 129 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2007 | 89 | 0.020 |
Why?
|
| Cell Separation | 1 | 2007 | 94 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 1804 | 0.020 |
Why?
|
| Cell Line | 1 | 2008 | 1416 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 928 | 0.010 |
Why?
|
| Decision Making | 1 | 2005 | 242 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 508 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 2111 | 0.010 |
Why?
|
| Time Factors | 1 | 2007 | 1848 | 0.010 |
Why?
|
| Sex Factors | 1 | 2004 | 1008 | 0.010 |
Why?
|